**All Interactions with Amprenavir (Agenerase)**

| **Coadministered Drug** | **Dose of Drug** | **Dose of Amprenavir** | **Effect on Drug Levels** | **Effect on Amprenavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Abacavir[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (ABC)(Ziagen) | 300 mg BID x 3 weeks | 900 mg BID x 3 weeks | Not studied | Amprenavir Cmax: increased 47%; AUC: increased 29%; Cmin: increased 27% | - | - | Dose adjustment not established |
| Alprazolam[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (Xanax) | - | - | Not studied; may increase alprazolam levels | - | Increased alprazolam effects (eg, increased sedation, confusion, respiratory depression) | Inhibition of CYP450 3A4 by amprenavir | Avoid combination; consider alternative agents  *Alternative Agents*:  **Lorazepam** |
| Amiodarone[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60) | - | - | Not studied; may increase amiodarone levels | - | Increased amiodarone effects (eg, hypotension, bradycardia, cardiac arrhythmias) | Inhibition of CYP450 3A4 by amprenavir | Monitor and adjust amiodarone as indicated |
| Antacids[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (Maalox, Mylanta, Riopan, Milk of Magnesia, others) | - | - | - | Decreased amprenavir levels | - | Decreased amprenavir bioavailability | Separate dosing by at least 1 hour |
| Astemizole[63](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#63),[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (Hismanal) | - | - | Not studied; may increase astemizole levels | - | Increased astemizole effects (eg, cardiac arrhythmias) | Inhibition of CYP450 3A4 by amprenavir | Do not coadminister  *Alternative Agents*:  **Cetirizine Fexofenadine Loratadine** |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Amprenavir** | **Effect on Drug Levels** | **Effect on Amprenavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Atorvastatin[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60) | - | - | Not studied; may increase atorvastatin levels | - | Increased atorvastatin effects (eg, myopathy, rhabdomyolysis) | Inhibition of CYP450 3A4 by amprenavir | Avoid combination if possible; may consider low dose atorvastatin or alternative agents; monitor for myopathy  *Alternative Agents*:  **Pravastatin** |
| Bepridil[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60) | - | - | Not studied; may increase bepridil levels | - | Increased bepridil effects | Inhibition of CYP450 3A4 by amprenavir | Do not coadminister |
| Carbamazepine[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (others)(Tegretol) | - | - | Not studied; may increase carbamazepine levels | Not studied; may decrease amprenavir levels | Decreased amprenavir effects; increased carbamazepine effects | Inhibition of CYP450 3A4 by amprenavir; induction of CYP450 3A4 by carbamazepine | Avoid combination if possible; consider alternative agents; monitor carbamazepine levels and adjust as indicated  *Alternative Agents*:  **Gabapentin Lamotrigine Tiagabine Topiramate** |
| Cimetidine[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (Tagamet)(Tagamet) | - | - | - | Not studied; may increase amprenavir levels | - | Inhibition of CYP450 3A4 by cimetidine | Consider alternative agents  *Alternative Agents*:  **Famotidine Nizatidine Ranitidine** |
| Cisapride[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (Propulsid) | - | - | Not studied; may increase cisapride levels | - | Increased cisapride effects (eg, cardiac arrhythmias) | Inhibition of CYP450 3A4 by amprenavir | Do not coadminister  *Alternative Agents*:  **Metoclopramide** |
| Clarithromycin[361](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#361),[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (Biaxin) | 500 mg BID x 7 doses | 1200 mg BID x 7 doses | Clarithromycin Cmax: no significant change; AUC: no significant change;14-hydroxy clarithromycin Cmax: decreased 32%; AUC: decreased 35% | Amprenavir Cmax: increased 15%; AUC: increased 18%; Cmin: increased 39% | - | Inhibition of CYP450 3A4 by amprenavir | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Amprenavir** | **Effect on Drug Levels** | **Effect on Amprenavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Clorazepate[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (Tranxene) | - | - | Not studied; may increase clorazepate levels | - | Increased clorazepate effects (eg, increased sedation, confusion, respiratory depression) | Inhibition of CYP450 3A4 by amprenavir | Avoid combination; consider alternative agents |
| Clozapine[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (Clozaril) | - | - | Not studied; may increase clozapine levels | - | Increased clozapine effects | - | Monitor and adjust clozapine as needed |
| Dapsone[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (others)(Avlosulfon) | - | - | - | Not studied; may increase amprenavir levels | - | - | No dose adjustment necessary |
| Delavirdine[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (DLV)(Rescriptor) | - | - | Not studied | Not studied; may increase amprenavir levels | - | Inhibition of CYP450 3A4 by delavirdine | Dose adjustment not established |
| Delavirdine[141](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#141)  (DLV)(Rescriptor) | 1000 mg BID x 10 days | 450 mg BID x 10 days | Delavirdine AUC: increased 126%; Cmin: increased 372%; Cmax: increased 115%(compared to amprenavir 600 mg and delavirdine 600 mg BID) | Amprenavir AUC: increased 20% | Increased delavirdine effects | Inhibition of CYP450 3A4 by amprenavir | Dose adjustment not established |
| Delavirdine[109](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#109)  (DLV)(Rescriptor) | 600 mg BID | 600 mg BID | Delavirdine AUC: decreased 61%; Cmax: decreased 47%; Cmin: decreased 88% | Amprenavir AUC: increased 130%; Cmax: increased 40%; Cmin: increased 125% | Decreased delavirdine and increased amprenavir effects | Induction of CYP450 3A4 by amprenavir and inhibition of CYP450 3A4 by delavirdine | Do not coadminister |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Amprenavir** | **Effect on Drug Levels** | **Effect on Amprenavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Delavirdine[110](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#110)  (DLV)(Rescriptor) | 600 mg BID | 600 mg BID | Delavirdine AUC: decreased 50%; Cmax: decreased 30%; Cmin: decreased 70% | Amprenavir AUC: increased 30%; Cmax: increased 18%; Cmin: increased 90% | Decreased delavirdine and increased amprenavir effects | Induction of CYP450 3A4 by amprenavir and inhibition of CYP450 3A4 by delavirdine | Do not coadminister |
| Diazepam[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (Valium) | - | - | Not studied; may increase diazepam levels | - | Increased diazepam effects (eg, increased sedation, confusion, respiratory depression) | Inhibition of CYP450 3A4 by amprenavir | Do not coadminister  *Alternative Agents*:  **Lorazepam Oxazepam Temazepam** |
| Didanosine[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (ddI)(Videx) | - | - | - | May decrease amprenavir bioavailability | Decreased amprenavir effects | Decreased amprenavir absorption | Separate didanosine and amprenavir doses by at least 1 hour |
| Didanosine[117](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#117)  (ddI)(Videx) | 2-200 mg (tablets) QD | 600 mg BID on days 1-4 and 15-18 | Not studied | No significant change | - | - | No dose adjustment necessary |
| Didanosine[117](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#117)  (ddI)(Videx) | 400 mg (enteric coated capsules) QD | 600 mg BID on days 1-4 and 15-18 | Not studied | No significant change | - | - | No dose adjustment necessary |
| Didanosine[127](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#127)  (ddI)(Videx) | 400 mg QD (buffered and enteric coated) x 4 days | 600 mg BID x 4 days | Not studied | No significant effect (with either didanosine formulation) | - | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Amprenavir** | **Effect on Drug Levels** | **Effect on Amprenavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Diltiazem[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (Dilacor, Tiazac, Cardizem) | - | - | May increase diltiazem levels | - | Increased diltiazem effects (eg, hypotension, heart block) | Inhibition of CYP450 3A4 by amprenavir | Monitor and adjust diltiazem as indicated |
| Disulfiram[211](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#211)  (Antabuse) | - | Oral solution (contains propylene glycol) | - | - | Propylene glycol toxicity (acidosis, CNS depression) | Inhibition of aldehyde dehydrogenase by disulfiram | Do not coadminister disulfiram with amprenavir oral solution  *Alternative Agents*:  **Amprenavir capsules** |
| Dofetilide[316](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#316)  (Tikosyn) | - | - | Not studied; may increase dofetilide levels | - | - | Inhibition of CYP450 3A4 by amprenavir | Monitor and adjust dofetilide as indicated |
| Efavirenz[94](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#94)  (EFV)(Sustiva) | - | - | Not studied | Amprenavir AUC: decreased 24%; Cmax: decreased 33%; Cmin: decreased 43% | Decreased amprenavir effects | Induction of CYP450 3A4 by efavirenz | Dose adjustment not established |
| Efavirenz[94](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#94),[62](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#62)  (EFV)(Sustiva) | 600 mg QD | 1200 mg BID | Not studied | Amprenavir AUC: decreased 24%; Cmax: decreased 33%; Cmin: decreased 43% | Decreased amprenavir effects | Induction of CYP450 3A4 by efavirenz | Increase amprenavir dose to 1200 mg TID when used as single PI; use combination amprenavir 1200 mg BID with ritonavir 200 mg BID |
| Efavirenz[90](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#90),[91](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#91),[112](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#112)  (EFV)(Sustiva) | 600 mg QD | 1200 mg BID | Not studied | Decreased mean amprenavir levels | Decreased amprenavir effects | Induction of CYP450 3A4 by efavirenz | May consider adding ritonavir or nelfinavir |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Amprenavir** | **Effect on Drug Levels** | **Effect on Amprenavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Efavirenz[94](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#94)  (EFV)(Sustiva) | 600 mg QD | 1200 mg BID | Not studied | AUC: decreased 24%; Cmax: decreased 33%; Cmin: decreased 43% | Decreased amprenavir effects | Induction of CYP450 3A4 by efavirenz | Dose adjustment not established |
| Efavirenz[121](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#121)  (EFV)(Sustiva) | 600 mg QD added to stable amprenavir/ritonavir regimen | 600 mg BID with ritonavir 100 mg BID | Not studied | Amprenavir AUC: decreased 40%; Cmax: decreased 42%; Cmin: decreased 29%; Ritonavir AUC: decreased 58%; Cmax: decreased 57%; Cmin: decreased 47% (compared to amprenavir 600 mb BID and ritonavir 100 mg BID) | When amprenavir and ritonavir are used with efavirenz, ritonavir is able to overcome the efavirenz induction so amprenavir levels are well above those of amprenavir alone | Induction of CYP450 3A4 by efavirenz | No dose adjustment necessary |
| Efavirenz[114](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#114)  (EFV)(Sustiva) | 600 mg QD on days 2-15 | 1200 mg QD with 200 mg ritonavir QD on day 1, then 300 mg ritonavir on days 2-15 | Not studied | No significant change | - | Inhibition of CYP450 3A4 by ritonavir | No dose adjustment necessary |
| Ergotamine[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (Cafergot, Ergot derivatives)(Cafergot, others) | - | - | Not studied; may increase ergotamine levels | - | Increased ergotamine effects (eg, ergotism) | Inhibition of CYP450 3A4 by amprenavir | Do not coadminister  *Alternative Agents*:  **5-HT agonists ("triptans")** |
| Erythromycin[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (E-Base, Ilosone, E-Mycin, Eryc, Ery-Tab, others)(Eryc, E-Base) | - | - | Not studied; may increase erythromycin levels | Not studied; may increase amprenavir levels | - | Inhibition of CYP450 3A4 by either drug | Dose adjustment not established  *Alternative Agents*:  **Azithromycin Clarithromycin** |
| Ethanol[211](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#211)  (Alcohol, Ethanol, Wine, Liquor, Beer, Spirits) | - | - | - | - | Propylene glycol toxicity (eg, acidosis, CNS depression) | Inhibition of alcohol and aldehyde dehydrogenase metabolism of propylene glycol by alcohol | Use of alcoholic beverages is not recommended with amprenavir oral solution  *Alternative Agents*:  **Amprenavir capsules** |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Amprenavir** | **Effect on Drug Levels** | **Effect on Amprenavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Ethinyl estradiol/norethindrone acetate[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (others)(Ortho-Novum) | 0.035 mg ethinyl estradiol/1 mg norethindrone x 1 cycle | 1200 mg BID x 28 days | Ethinyl estradiol Cmin: increased 32%; Norethindrone AUC: increased 18%; Cmin: increased 45% | Amprenavir AUC: decreased 22%; Cmin: decreased 20% | Unknown effect on birth control | Not established | Dose adjustment not established; may need to use alternative method of birth control  *Alternative Agents*:  **Barrier devices, condoms** |
| Flurazepam[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (Dalmane)(Dalmane) | - | - | Not studied; may increase flurazepam levels | - | Increased flurazepam effects (eg, increased sedation, confusion, respiratory depression) | Inhibition of CYP450 3A4 by amprenavir | Avoid combination; consider alternative agents  *Alternative Agents*:  **Lorazepam Oxazepam Temazepam Trazodone** |
| Fosphenytoin[222](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#222)  (Cerebyx)(Cerebyx) | - | - | - | Not studied; may decrease amprenavir levels | Decreased amprenavir effects | Inhibition of CYP450 3A4 by amprenavir; induction of CYP450 3A4 by phenytoin | Dose adjustment not established |
| Indinavir[111](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#111)  (IDV)(Crixivan) | 1200 mg BID | 1200 mg BID with efavirenz 600 mg QD | Not studied | Amprenavir clearance: decreased 54% | - | Induction of CYP450 3A4 by amprenavir or efavirenz | Dose adjustment not established |
| Indinavir[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60),[63](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#63)  (IDV)(Crixivan) | 750 mg or 800 mg TID x 2 weeks (fasted) | 800 mg TID x 2 weeks (fasted) | Indinavir AUC: decreased 38%; Cmax: decreased 22%; Cmin: decreased 27% | Amprenavir AUC: increased 33%; Cmax: increased 18%; Cmin: increased 25% | - | Inhibition of CYP450 3A4 by indinavir; induction of CYP450 3A4 by amprenavir | No dose adjustment necessary |
| Indinavir[254](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#254),[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (IDV)(Crixivan) | 800 mg TID (fasted) | 750 mg or 800 mg TID (fasted) | Indinavir Cmax: decreased 22%; AUC: decreased 38%; Cmin: decreased 27% | Amprenavir Cmax: increased 18%; AUC: increased 33%; Cmin: increased 25% | - | Inhibition of CYP450 3A4 by indinavir | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Amprenavir** | **Effect on Drug Levels** | **Effect on Amprenavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Itraconazole[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (Sporanox)(Sporanox) | - | - | Not studied; may increase itraconazole levels | Not studied; may increase amprenavir levels | - | Inhibition of CYP450 3A4 by either drug | Dose adjustment not established |
| Ketoconazole[284](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#284),[63](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#63),[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (Nizoral) | 400 mg x 1 dose | 1200 mg x 1 dose | Ketoconazole AUC: increased 44%; Cmax: increased 19% | Amprenavir AUC: increased 31%; Cmax: decreased 16% | No significant change | Inhibition of gastrointestinal and hepatic CYP450 3A4 by amprenavir; inhibition of P-glycoprotein by amprenavir; inhibition of CYP 3A4 by ketoconazole | Dose adjustment not established |
| Lamivudine[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (3TC)(Epivir) | 150 mg x 1 dose | 150 mg x 1 dose | No significant change | No significant change | - | - | No dose adjustment necessary |
| Lidocaine[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (Xylocaine) | Systemic lidocaine | - | Not studied; may increase lidocaine levels | - | Increased lidocaine effects | Inhibition of CYP450 3A4 by amprenavir | Monitor and adjust lidocaine as indicated |
| Lopinavir/ritonavir[65](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#65)  (LPV/r)(Kaletra) | 400 mg/100 mg BID | 600 mg BID | Not studied | Amprenavir Cmin: decreased 37% (when compared to standard curve obtained from amprenavir and ritonavir at same doses) | Decreased amprenavir levels | Not established | Dose adjustment not established |
| Lopinavir/ritonavir[78](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#78),[79](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#79)  (LPV/r)(Kaletra) | 400 mg/100 mg BID x 22 days | 450 mg BID x 5 days, 750 mg BID x 5 days | Lopinavir AUC: decreased 15%; lopinavir Cmax: no significant change; Cmin: decreased 19% | No significant change | - | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Amprenavir** | **Effect on Drug Levels** | **Effect on Amprenavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Lopinavir/ritonavir[64](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#64)  (LPV/r)(Kaletra) | 400 mg/100 mg BID x weeks 2-26 | Group 2: 1200 mg amprenavir/200 mg ritonavir BID; Group 4: 1200 mg amprenavir/400 mg ritonavir BID x weeks 1-26 | Not studied | Amprenavir Cmin: decreased 42% (in Group 2); Cmin decreased 69% (in Group 4) | Decreased amprenavir levels | - | Dose adjustment not established |
| Lopinavir/ritonavir[151](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#151)  (LPV/r)(Kaletra) | 533mg/133 mg BID with and without efavirenz 600 mg QHS | 750 mg BID | Lopinavir AUC: no significant change; Cmax: no significant change; Cmin: no significant change; half-life: decreased 32%(when compared to amprenavir, lopinavir/ritonavir with efavirenz) | Amprenavir AUC: no significant change; Cmax: decreased 34%; Cmin: increased 22%(when compared to amprenavir, lopinavir/ritonavir with efavirenz) | - | - | No dose adjustment necessary |
| Lovastatin[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (Mevacor)(Mevacor) | - | - | Not studied; may increase lovastatin levels | - | Increased lovastatin effects (eg, myopathy, rhabdomyolysis) | Inhibition of CYP450 3A4 by amprenavir | Do not coadminister  *Alternative Agents*:  **Atorvastatin Pravastatin** |
| Methadone[189](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#189)  (Dolophine)(Dolophine) | - | 1200 mg BID | Methadone concentration: decreased 35% | - | Decreased methadone effects (eg, withdrawal) | Possible induction of CYP450 3A4 by amprenavir | Monitor for signs and symptoms of methadone withdrawal; Some patients may need an increase in the methadone dose |
| Methadone[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (Dolophine)(Dolophine) | 44-100 mg QD for more than 30 days | 1200 mg BID x 10 days | R-methadone AUC: no significant change; Cmax: decreased 25%; Cmin: decreased 21%; S-methadone AUC: decreased 40%; Cmax: decreased 48%; Cmin: decreased 53% | - | Decreased methadone effects (eg, withdrawal) | Induction of CYP450 3A4 by amprenavir | Monitor for signs and symptoms of methadone withdrawal; some patients may need an increase in the methadone dose |
| Methadone[182](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#182)  (Dolophine)(Dolophine) | stable daily dose | 1200 mg BID | R-methadone AUC: no significant change; Cmax: decreased 25%; Cmin: decreased 21%;S-methadone AUC: decreased 40%; Cmax: decreased 48%; Cmin: decreased 52% | - | - | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Amprenavir** | **Effect on Drug Levels** | **Effect on Amprenavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Methadone[182](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#182)  (Dolophine)(Dolophine) | stable dose | 1200 mg BID x 10 days | R-methadone AUC: no significant change; Cmax: decreased 25%; Cmin: decreased 21%; S-methadone AUC: decreased 40%; Cmax: decreased 48%; Cmin: decreased 52% | - | Decreased methadone effects (eg, withdrawal) | Possible induction of CYP450 3A4 by amprenavir | Monitor for signs and symptoms of methadone withdrawal; some patients may need an increase in the methadone dose |
| Metronidazole[211](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#211)  (Flagyl)(Flagyl) | - | Oral solution (contains propylene glycol) | - | - | Propylene glycol toxicity (eg, acidosis, CNS depression) | Inhibition of alcohol and aldehyde dehydrogenase by metronidazole | Do not coadminister with amprenavir oral solution  *Alternative Agents*:  **Amprenavir capsules** |
| Midazolam[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (Versed) | - | - | Not studied; may increase midazolam levels | - | Increased midazolam effects (eg, increased sedation, confusion, respiratory depression) | Inhibition of CYP450 3A4 by amprenavir | Parenteral midazolam can be used with caution when given as a single dose in a monitored situation for procedural sedation; chronic midazolam administration (oral or intravenous) should be avoided  *Alternative Agents*:  **Lorazepam** |
| Nelfinavir[111](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#111)  (NFV)(Viracept) | 1250 mg BID | 1200 mg BID with efavirenz 600 mg QD | Not studied | Amprenavir clearance: decreased 41% | - | Induction of CYP450 3A4 by amprenavir or efavirenz | Dose adjustment not established |
| Nelfinavir[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (NFV)(Viracept) | 750 mg TID x 2 weeks (fed) | 750 mg or 800 mg TID x 2 weeks (fed) | Nelfinavir AUC: increased 15%; Cmax: no significant change; Cmin: no significant change | Amprenavir AUC: no significant change; Cmax: no significant change; Cmin: increased 189% | Increased amprenavir effects | Inhibition of CYP450 3A4 by both drugs | No dose adjustment necessary |
| Nelfinavir[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (NFV)(Viracept) | 750 mg TID x 2 weeks (fed) | 750 mg or 800 mg TID x 2 weeks (fed) | Nelfinavir AUC: increased 15%; Cmax: no significant change | No significant change | - | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Amprenavir** | **Effect on Drug Levels** | **Effect on Amprenavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Nevirapine[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (NVP)(Viramune) | - | - | - | May decrease amprenavir levels | Decreased amprenavir effects | Induction of CYP450 3A4 by nevirapine | Dose adjustment not established |
| Nicardipine[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (Cardene)(Cardene) | - | - | Not studied; may increase nicardipine levels | - | Increased nicardipine effects (eg, hypotension, heart block) | Inhibition of CYP450 3A4 by amprenavir | Monitor and adjust nicardipine as indicated |
| Nifedipine[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (Procardia, Adalat)(Adalat, Procardia) | - | - | Not studied; may increase nifedipine levels | - | Increased nifedipine effects (hypotension, heart block) | Inhibition of CYP450 3A4 by amprenavir | Monitor and adjust nifedipine as indicated |
| Nimodipine[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (Nimotop)(Nimotop) | - | - | Not studied; may increase nimodipine levels | - | Increased nimodipine effects (eg, hypotension, heart block) | Inhibition of CYP450 3A4 by amprenavir | Monitor and adjust nimodipine as indicated |
| Phenobarbital[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (others)(Luminal) | - | - | - | Not studied; may decrease amprenavir levels | Decreased amprenavir effects | Induction of CYP450 3A4 by phenobarbital | Avoid combination if possible; consider alternative agents. If using, monitor and adjust phenobarbital levels as indicated.  *Alternative Agents*:  **Gabapentin Lamotrigine Tiagabine Topiramate** |
| Phenytoin[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (Dilantin) | - | - | - | Not studied; may decrease amprenavir levels | Decreased amprenavir effects | Induction of CYP450 3A4 by phenytoin | Avoid combination if possible; consider alternative agents. Monitor phenytoin levels and adjust as indicated. Monitor virologic response.  *Alternative Agents*:  **Gabapentin Lamotrigine Tiagabine Topiramate** |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Amprenavir** | **Effect on Drug Levels** | **Effect on Amprenavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Pimozide[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (Orap)(Orap) | - | - | Not studied; may increase pimozide levels | - | Increased pimozide effects (eg, hypotension, cardiac arrhythmias) | Inhibition of CYP450 3A4 by amprenavir | Do not coadminister |
| Quinidine[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (Quindex, others)(Quindex) | - | - | Not studied; may increase quinidine levels | - | Increased quinidine effects (eg, cardiac arrhythmias, exacerbation of heart failure) | Inhibition of CYP450 3A4 by amprenavir | Monitor and adjust quinidine as indicated |
| Rifabutin[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60),[62](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#62),[63](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#63)  (Mycobutin) | 300 mg QD x 10 days | 1200 mg BID x 10 days | Rifabutin AUC: increased 193%; Cmax: increased 119%; Cmin: increased 271% | Amprenavir AUC: decreased 15%; Cmax: no significant change; Cmin: decreased 15% | Increased rifabutin effects (eg, uveitis) | Inhibition of CYP450 3A4 by amprenavir | Reduce rifabutin dose to 150 mg daily or 300 mg 3x/week. Monitor for antimicrobial activity and/or consider therapeutic drug monitoring. |
| Rifabutin[340](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#340)  (Mycobutin) | 300 mg QD x 14 days | 1200 mg BID | Rifabutin AUC: increased 193%; Cmax: increased 119%; 25-O-desacetylrifabutin AUC: increased 1230%; clearance: decreased 66% | No significant change | Increased rifabutin effects (eg, uveitis) | Inhibition of CYP450 3A4 by amprenavir | Reduce rifabutin dose to 150 mg daily or 300 mg 3x/week. Monitor for antimicrobial activity and/or consider therapeutic drug monitoring. |
| Rifampin[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (Rifampicin)(Rifadin) | 300 mg QD x 4 days | 1200 mg BID x 4 days | No significant change | Amprenavir AUC: decreased 82%; Cmax: decreased 70%; Cmin: decreased 92% | Decreased amprenavir effects | Induction of CYP450 3A4 by rifampin | Do not coadminister  *Alternative Agents*:  **Rifabutin** |
| Rifampin[340](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#340)  (Rifampicin)(Rifadin) | 600 mg QD x 14 days | 1200 mg BID | No significant change | AUC: decreased 82% | Decreased amprenavir effects | Induction of CYP450 3A4 by rifampin | Do not coadminister  *Alternative Agents*:  **Rifabutin** |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Amprenavir** | **Effect on Drug Levels** | **Effect on Amprenavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Ritonavir[63](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#63),[53](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#53)  (RTV)(Norvir) | - | - | Not studied | Increased amprenavir levels | Increased amprenavir effects | Inhibition of CYP450 3A4 by ritonavir | Dose adjustment not established |
| Ritonavir[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (RTV)(Norvir) | 100 mg BID x 2-4 weeks | 600 mg BID | Not studied | Amprenavir AUC: increased 64%; Cmax: decreased 30%; Cmin: increased 508% | Increased amprenavir effects | Inhibition of CYP450 3A4 by ritonavir | - |
| Ritonavir[116](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#116)  (RTV)(Norvir) | 100 mg on days 8-14, 200 mg QD on days 15-21 | 1200 mg QD on days 1-7 | Not studied | Amprenavir AUC: increased 119%; Cmax: no significant change; Cmin: increased 840% (with 100 mg ritonavir); no significant change with 200 mg ritonavir | Increased amprenavir effects | Inhibition of CYP450 3A4 by ritonavir | Dose adjustment not established |
| Ritonavir[115](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#115)  (RTV)(Norvir) | 100 mg Q12H | 900 mg Q12H | Ritonavir AUC: decreased 64%; Cmax: decreased 32%; Cmin: decreased 65% | Amprenavir AUC: increased 109%; Cmax: no significant change; Cmin: increased 585% | Increased amprenavir effects | Inhibition of CYP450 3A4 by ritonavir and induction of CYP450 3A4 by amprenavir | Dose adjustment not established |
| Ritonavir[112](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#112)  (RTV)(Norvir) | 200 mg BID | 1200 mg BID | Not studied | Amprenavir AUC: increased 127%; Cmin: increased 395%; | Increased amprenavir effects | Inhibition of CYP450 3A4 by ritonavir | No dose adjustment necessary |
| Ritonavir[112](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#112)  (RTV)(Norvir) | 200 mg BID | 1200 mg BID with efavirenz 600 mg QD | Not studied | No significant change | - | Inhibition of CYP450 3A4 by ritonavir and induction of CYP450 3A4 by efavirenz | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Amprenavir** | **Effect on Drug Levels** | **Effect on Amprenavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Ritonavir[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (RTV)(Norvir) | 200 mg BID x 2-4 weeks | 1200 mg QD | Not studied | Amprenavir AUC: increased 62%; Cmin: increased 319% | Increased amprenavir effects | Inhibition of CYP450 3A4 by ritonavir | Dose adjustment not established |
| Ritonavir[112](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#112)  (RTV)(Norvir) | 500 mg BID | 1200 mg BID | Not studied | Amprenavir AUC: increased 143%; Cmin: increased 576% | Increased amprenavir effects | Inhibition of CYP450 3A4 by ritonavir | Dose adjustment not established |
| Saquinavir[111](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#111)  (SQV)(Fortovase, Invirase) | 1600 mg BID (soft gel caps) | 1200 mg BID with efavirenz 600 mg QD | Not studied | Amprenavir clearance: no significant change | - | - | No dose adjustment necessary |
| Saquinavir[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (SQV)(Fortovase, Invirase) | 800 mg TID x 2 weeks (fed) | 750 mg or 800 mg TID x 2 weeks (fed) | Saquinavir AUC: decreased 19%; Cmax: increased 21%; Cmin: decreased 48% | Amprenavir AUC: decreased 32%; Cmax: decreased 37%; Cmin: no significant change | Decreased amprenavir effects | Induction of CYP450 3A4 by either drug | No dose adjustment necessary |
| Sildenafil[739](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#739),[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60),[727](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#727)  (Viagra) | - | - | Not studied; may increase sildenafil levels | - | Potentially increased sildenafil effects (eg, hypotension, priapism) | Inhibition of CYP450 3A4 by amprenavir | For erectile dysfunction, initiate sildenafil 25 mg every 48 hours and monitor for adverse effects. Manufacturer recommends not to exceed dose of 25 mg every 48 hours. Do not coadminister if using sildenafil for pulmonary arterial hypertension. |
| Simeprevir[727](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#727)  (Olysio) | - | - | - | - | - | Inhibition of CYP3A4 potentiating simeprevir effects | Do not coadminister |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Amprenavir** | **Effect on Drug Levels** | **Effect on Amprenavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Simvastatin[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (Zocor)(Zocor) | - | - | Not studied; may increase simvastatin levels | - | Increased simvastatin effects (eg, myopathy, rhabdomyolysis) | Inhibition of CYP450 3A4 by amprenavir | Do not coadminister  *Alternative Agents*:  **Atorvastatin Pravastatin** |
| St. John's Wort[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (Hypericum perforatum, hypericin, hyperforin) | - | - | Not studied | Not studied; may decrease amprenavir levels | May decrease amprenavir effects | Induction of CYP450 3A4 by St. John's Wort | Do not coadminister |
| Terfenadine[63](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#63),[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (Seldane)(Seldane) | - | - | Not studied; may increase terfenadine levels | - | Increased terfenadine effects (eg, cardiac arrhythmias) | Inhibition of CYP450 3A4 by amprenavir | Do not coadminister  *Alternative Agents*:  **Cetirizine Fexofenadine Loratadine** |
| Tinidazole[329](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#329),[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (Tindamax) | - | Oral solution (contains propylene glycol) | - | - | Propylene glycol toxicity (eg, acidosis, CNS depression) | Inhibition of alcohol and aldehyde dehydrogenase by tinidazole | Do not coadminister with amprenavir oral solution  *Alternative Agents*:  **Amprenavir capsules** |
| Tipranavir[154](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#154)  (TPV)(Aptivus) | 500 mg BID with 200 mg ritonavir BID x 28 doses | 600 mg BID with 100 mg ritonavir BID x 27 doses | - | Amprenavir AUC: decreased 44%; Cmax: decreased 39%; Cmin: decreased 56% | Decreased amprenavir effects | Possible induction of CYP450 3A4 by tipranavir/ritonavir | Do not coadminister |
| Triazolam[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (Halcion) | - | - | Not studied; may increase triazolam levels | - | Increased triazolam effects (eg, increased sedation, confusion, respiratory depression) | Inhibition of CYP450 3A4 by amprenavir | Do not coadminister; consider alternative agents  *Alternative Agents*:  **Lorazepam Oxazepam Temazepam Trazodone** |
| Warfarin[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (Coumadin) | - | - | Not studied; may increase warfarin effects | - | Increased warfarin effects (eg, increased INR, increased risk of bleeding) | Inhibition of CYP450 3A4 by amprenavir | Monitor INR and adjust warfarin as indicated |
| Zidovudine[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=15&post=4#60)  (AZT, ZDV)(Retrovir) | 300 mg x 1 dose | 600 mg x 1 dose | Zidovudine AUC: increased 31%; Cmax: increased 40% | No significant change | - | - | No dose adjustment necessary |
| "-" indicates that there are no data available | | | | | | | |

|  |  |
| --- | --- |
| 53: | Sadler BM, Piliero PJ, Preston SL, et al. Pharmacokinetic (PK) drug-interaction between amprenavir (APV) and ritonavir (RTV) in HIV-seronegative subjects after multiple, oral dosing [abstract #77]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco, California. |
| 60: | Agenerase [package insert]. Research Triangle Park, NC: Glaxo Wellcome Inc; 2004. |
| 62: | Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. August 13, 2001. |
| 63: | Decker CJ, Laitinen LM, Bridson GW, et al. Metabolism of amprenavir in liver microsomes: Role of CYP3A4 inhibition for drug interactions. J Pharm Sci 1998;87:803-7. |
| 64: | Raguin G, Taburet AM, Chene G, et al. Pharmacokinetic parameters and virological response to the combination of lopinavir/ritonavir (LPV/r) and amprenavir (APV) in HIV-infected patients with multiple treatment failures: week-6 results of Puzzle 1-ANRS study [abstract #420]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle, Washington. |
| 65: | Baldini F, Rizzo MG, Hoetelmans RMW, et al. A prospective study of deep salvage therapy with lopinavir/r, amprenavir, and NRTIs: final 24-week data, pharmacokinetics and association of drug levels/drug susceptibility with virologic response [abstract #423]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle, Washington. |
| 78: | Kaletra [package insert]. North Chicago, IL: Abbott Laboratories; Oct 2005. |
| 79: | Hsu A, Bertz R, Ashbrenner E, et al. Interaction of ABT-378/ritonavir with protease inhibitors in healthy volunteers [abstract #2.4]. 1st International Workshop on Clinical Pharmacology of HIV Therapy; 2000 March 30-April 1; Noordwijk, The Netherlands. |
| 90: | Sustiva [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; Dec 2011. |
| 91: | Duval X, Moing VL, Longuet P, et al. Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir. Antimicrob Agents Chemother 2000;44:2593. |
| 94: | Falloon J, Piscitelli S, Vogel S, et al. Combination therapy with amprenavir, abacavir and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. Clin Infect Dis 2000;30:313-18. |
| 109: | Justesen US, Klitgaard NA, Brosen K, Pedersen C. Amprenavir is an effective inducer of delavirdine metabolism [abstract #442-W]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 February 24-28; Seattle, Washington. |
| 110: | Tran JQ, Petersen C, Garrett M, et al. Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir. Clin Pharmacol Ther 2002;72:615-26. |
| 111: | Pfister M, Labbe L, Lu J-F, et al. Effect of coadministration of nelfinavir, indinavir and saquinavir on the pharmacokinetics of amprenavir. Clin Pharmacol Ther 2002;72:133-41. |
| 112: | Piscitelli S, Bechtel C, Sadler B, et al. The addition of a second protease inhibitor eliminates amprenavir-efavirenz drug interactions and increases plasma amprenavir concentrations [abstract #78]. 7th Conference on Retroviruses and Opportunitic Infections; 2000 January 30-February 4; San Francisco, California. |
| 114: | Wood R, Wire MB, Lancaster CT, et al. An assessment of plasma amprenavir pharmacokinetics following administration of Agenerase and low dose ritonavir QD in combination with efavirenz in HIV-infected adult subjects (COL30500) [abstract #2.6]. 3rd International Workshop on Clinical Pharmacology of HIV Therapy; 2002 April 11-13; Washington, D.C. |
| 115: | Sadler BM, Piliero PJ, Preston SL, et al. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers. AIDS 2001;15:1009-18. |
| 116: | Kurowski M, Staszewski S, Arslan A, et al. Influence of 50 mg, 100 mg and 200 mg ritonavir on the pharmacokinetics of amprenavir after multiple doses in healthy volunteers for once daily and twice daily regimens [abstract #351]. 1st IAS Conference on HIV Pathogenesis and Treatment; 2001 July 8-11; Buenos Aires, Argentina. |
| 117: | Shelton MJ, Giovanniello AG, Cloen D, et al. The effects of didanosine formulations on the pharmacokinetics of amprenavir [abstract #A-1826]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 September 27-30; Chicago, Illinois. |
| 121: | Goujard C, Vincent I, Meynard JL, et al. Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 2003;47:118-23. |
| 127: | Shelton MJ, Giovanniello AA, Cloen D, et al. Effects of didanosine formulations on the pharmacokinetics of amprenavir. Pharmacotherapy 2003; 23: 835-42. |
| 141: | Justesen US, Klitgaard NA, Brosen K, et al. Dose-dependent pharmacokinetics of delavirdine in combination with amprenavir in healthy volunteers. J Antimicrob Chemother 2004; May 18th |
| 151: | Pham P, Barditch-Crovo P, Redpath E, et al. Steady-state pharmacokinetics of amprenavir, lopinavir and efavirenz combination in HIV-infected patients [abst. #79]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 February 22-25; Boston, Massachusetts. |
| 154: | Aptivus [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; Nov 2005. |
| 182: | Hendrix CW, Wakeford J, Wire MB, et al. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects. Pharmacother 2004; 24: 1110-21. |
| 189: | Bart P-A, Rizzardi PG, Gallant S, et al. Methadone blood concentrations are decreased by administration of abacavir plus amprenavir. Ther Drug Monit 2001;23:553-555. |
| 211: | Agenerase Oral Solution [package insert]. Research Triangle Park, NC: Glaxo Wellcome Inc; 2004. |
| 222: | Cerebyx [package insert]. Morris Plains, NJ: Parke-Davis; 1999. |
| 254: | CDC. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Jan 28, 2000. [AIDS Treatment Information Service: Current Treatment] Available at: http://www.hivatis.org/trtgdlns.html. |
| 284: | Polk RE, Crouch MA, Israel DS, et al. Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men. Pharmacotherapy 1999;19:1378-84. |
| 316: | Tikosyn [package insert]. New York, NY: Pfizer; 1999. |
| 329: | Tinidazole drug monograph. Grasberger F and Mutschler E. Micromedex 2002. |
| 340: | Polk RE, Brophy DF, Israel DS, et al. Pharmacokinetic interaction between amprenavir and rifabutin or rifampin in healthy males. Antimicrob Agents Chemother 2001;45:502-8. |
| 361: | Brophy DF, Israel DS, Pastor A, et al. Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers. Antimicrob Agents Chemother 2000;44: 978-84. |
| 727: | Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. |
| 739: | Viagra [package insert]. Pfizer Inc, Mission, KS, 2016. |